Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL30516238

CN1CCC(NC(=O)c2cc3nc(-c4ccccc4)cc(N4CCCCC4)n3n2)C1.O=C(O)C(F)(F)F

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.56
HTT P42858 2/20 0.56
CHRNB2 P17787 3/20 0.47
CHRNB4 P30926 3/20 0.47
CHRNA3 P32297 3/20 0.47
CHRNA4 P43681 3/20 0.47
ABCB1 P08183 1/20 0.45
ALDH1A1 P00352 10/20 0.45
MAPT P10636 7/20 0.45
HPGD P15428 6/20 0.45
HSD17B10 Q99714 2/20 0.45
NPSR1 Q6W5P4 5/20 0.45
LMNA P02545 4/20 0.45
L3MBTL1 Q9Y468 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
MAPK1 P28482 2/20 0.45
TP53 P04637 1/20 0.45
POLB P06746 4/20 0.44
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL31579036 1.00 KDM4E (0.56) KDM4EHTTCHRNB2CHRNB4CHRNA3
Trifluoroacetic Acid SCHEMBL31579090 1.00 KDM4E (0.56) KDM4EHTTCHRNB2CHRNB4CHRNA3
SCHEMBL25969726 0.95 KDM4E (0.61) KDM4EHTTCHRNB2CHRNB4CHRNA3
Trifluoroacetic Acid SCHEMBL30516225 0.94 KDM4E (0.56) KDM4EHTTABCB1ALDH1A1MAPT
SCHEMBL25969729 0.90 KDM4E (0.66) KDM4EHTTABCB1ALDH1A1MAPT
SCHEMBL25969588 0.89 KDM4E (0.62) KDM4EHTTABCB1ALDH1A1MAPT
SCHEMBL25338396 0.83 KDM4E (0.74) KDM4EHTTCHRNB2CHRNB4CHRNA3
SCHEMBL25968912 0.83 KDM4E (0.74) KDM4EHTTCHRNB2CHRNB4CHRNA3
SCHEMBL25335602 0.83 KDM4E (0.74) KDM4EHTTCHRNB2CHRNB4CHRNA3
SCHEMBL25338703 0.82 KDM4E (0.60) KDM4EHTTABCB1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250161307-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE JANSSEN PHARMACEUTICA NV (BE) 2025-05-22 US disclosed
EP-4469454-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE Janssen Pharmaceutica NV (BE) 2024-12-04 EP disclosed
WO-2023141866-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161307-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE SMOX, SRM, SMS KDM4E 1480/4885HTT 3140/4885CHRNB2 1326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.